WHO ICTRP trial
Genetic screening for GBA1 in Parkinson’s disease patients
ISRCTN99451262 · International Standard Randomised Controlled Trial Number (ISRCTN) · Recruiting
Key facts
| Trial ID | ISRCTN99451262 |
|---|---|
| Public title | Genetic screening for GBA1 in Parkinson’s disease patients |
| Scientific title | Genetic screening in Parkinson’s disease patients to identify GBA1 mutation carriers for future clinical trials |
| Primary sponsor | Vanqua Bio Inc. |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Recruiting |
| Study type | Observational |
| Phase | Not Applicable |
| Countries | Netherlands |
| Conditions | Parkinson's disease, Parkinsonism Nervous System Diseases |
| Interventions | Parkinson’s disease (PD) is a common neurodegenerative disease, present in 1-2% of individuals aged = 65 years. The most common genetic risk factor for PD is a heterozygous mutation in the GBA1 gene. In a previous study, it was demonstrated… |
| Registration date | Aug 11, 2023 |
| Target size | 1000 |
| Secondary IDs | Nil known;Nil known;CHDR2327/VQ-002 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: